OK
Accueil > Communauté > Forum Ab Science

Masitinib le nouveau paradigme du 13/09/2019

Cours temps réel: 14,41  2,42%



thedune3 thedune3
16/09/2019 08:31:35
1

Bonjour trady77 , merci du partage et andiamo ab , les news s'approchent tic tac tic tac :))

  
Répondre
Trady77 Trady77
16/09/2019 08:25:29
0

Reprise de la NEWS d'Abolivie sur le forum BOURSORAMA.

  
Répondre
Trady77 Trady77
16/09/2019 08:22:46
1

Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib.

Aljoundi AK, et al. Future Med Chem. 2019.

Show full citation

Abstract

AIM: Blocking oncogenic signaling of B-cell receptor (BCR) has been explored as a viable strategy in the treatment of diffuse large B-cell lymphoma. Masitinib is shown to multitarget LYN, FYN and BLK kinases that propagate BCR signals to downstream effectors. However, the molecular mechanisms of its selectivity and pan-inhibition remain elusive.


MATERIALS & METHODS: This study therefore employed molecular dynamics simulations coupled with advanced post-molecular dynamics simulation techniques to unravel the structural mechanisms that inform the reported multitargeting ability of masitinib.


RESULTS: Molecular dynamics simulations revealed initial selective targeting of catalytic residues (Asp334/Glu335 - LYN, Asp130/Asp148/Glu54 - FYN, Asp89 - BLK) by masitinib, with high-affinity interactions via its piperazine ring at the entrance of the ATP-binding pockets, before systematic access into the hydrophobic deep pocket grooves.


CONCLUSION: Identification of these 'gatekeeper' residues could open up a novel paradigm of structure-based design of highly selective pan-inhibitors of BCR signaling in the treatment of diffuse large B-cell lymphoma.


PMID 31516031 [ - as supplied by publisher]

Full text

Full text at journal site

Similar articles

Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.

Fallacara AL, et al. Eur J Med Chem. 2019.

SH2 domains of the protein-tyrosine kinases Blk, Lyn, and Fyn bind distinct sets of phosphoproteins from B lymphocytes.

Malek SN, et al. J Biol Chem. 1993.

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.

Battistello E, et al. Blood. 2018.

Role of src-like protooncogenes in lymphocyte proliferation.

Review article

Yamamoto T, et al. Princess Takamatsu Symp. 1991.

Structural aspects of signal transduction in B-cells.

  
Répondre
Trady77 Trady77
16/09/2019 08:21:05
1

2019 Sep 13. doi: 10.4155/fmc-2018-0354. [Epub ahead of print]

'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib.

Aljoundi AK1, Agoni C1, Olotu FA1, Soliman ME1.

Author information

1

Molecular Bio-computation & Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4001, South Africa.

Abstract

Aim: Blocking oncogenic signaling of B-cell receptor (BCR) has been explored as a viable strategy in the treatment of diffuse large B-cell lymphoma. Masitinib is shown to multitarget LYN, FYN and BLK kinases that propagate BCR signals to downstream effectors. However, the molecular mechanisms of its selectivity and pan-inhibition remain elusive. Materials & methods: This study therefore employed molecular dynamics simulations coupled with advanced post-molecular dynamics simulation techniques to unravel the structural mechanisms that inform the reported multitargeting ability of masitinib. Results: Molecular dynamics simulations revealed initial selective targeting of catalytic residues (Asp334/Glu335 - LYN, Asp130/Asp148/Glu54 - FYN, Asp89 - BLK) by masitinib, with high-affinity interactions via its piperazine ring at the entrance of the ATP-binding pockets, before systematic access into the hydrophobic deep pocket grooves. Conclusion: Identification of these 'gatekeeper' residues could open up a novel paradigm of structure-based design of highly selective pan-inhibitors of BCR signaling in the treatment of diffuse large B-cell lymphoma.


KEYWORDS:

B-cell receptor; BLK; FYN; LYN; SRC kinases; diffuse large B-cell lymphoma; molecular dynamics simulation; pan-inhibition


PMID: 31516031 DOI: 10.4155/fmc-2018-0354

Share on FacebookShare on TwitterShare on Google+

LinkOut - more resources

Supplemental Content

Full text links

Icon for Atypon

Save items

View more options

Similar articles

Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.

[Eur J Med Chem. 2019]

SH2 domains of the protein-tyrosine kinases Blk, Lyn, and Fyn bind distinct sets of phosphoproteins from B lymphocytes.

[J Biol Chem. 1993]

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.

[Blood. 2018]

Review Role of src-like protooncogenes in lymphocyte proliferation.

[Princess Takamatsu Symp. 1991]

Review Structural aspects of signal transduction in B-cells.

[Crit Rev Immunol. 1996]

See reviews...

See all...

Recent Activity

ClearTurn Off

'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC k...

PubMed

See more...

You are here: NCBI > Literature > PubMedSupport Center


  
Répondre
Trady77 Trady77
16/09/2019 08:19:16
1
Trady77 Trady77
16/09/2019 08:18:36
1

Forum de discussion Ab Science

201909160831 713096
logiciel chart 365 Suivez les marchés avec des outils de pros !

Chart365 par ABC Bourse, est une application pour suivre les marchés et vos valeurs favorites dans un environnement pensé pour vous.